Kymera Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kymera Therapeutics, Inc. on February 26, 2026. The filing details the entry into a new material definitive agreement for an "at-the-market" equity offering program and the termination of a prior sales agreement.
Key Financial Metrics and Capital Activities
- ATM Program Size: The Company may issue and sell up to $500,000,000 of common stock under the new agreement.
- Commission Rate: TD Securities (USA) LLC will receive a commission of up to 3.0% of gross proceeds from shares sold.
- Resale Registration: A prospectus supplement was filed to register the potential resale by Selling Stockholders of up to 18,819,826 shares of common stock and 12,565,253 shares issuable upon exercise of pre-funded warrants.
- Proceeds Impact: The filing of the resale prospectus supplement does not generate proceeds for the Company. Proceeds would only be received if pre-funded warrants are exercised for cash.
- Financial Statements: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics.
Material Changes Versus Prior Period
- New Sales Agreement: Entered into a Sales Agreement with TD Securities (USA) LLC on February 26, 2026, replacing the previous arrangement.
- Termination of Prior Agreement: Terminated the Open Market Sale Agreement with Jefferies LLC, dated October 31, 2024, effective immediately on February 26, 2026.
Guidance, Outlook, and Risks
- Discretionary Sales: The Company is not obligated to sell any shares under the new TD Cowen Sales Agreement, and TD Cowen is not required to sell any specific amount.
- Suspension Rights: Either party may suspend or terminate the offering upon notice.
- Resale Uncertainty: The resale registration for Selling Stockholders does not guarantee that any shares or warrants will be sold.
- Legal Opinion: Goodwin Procter LLP issued opinions regarding the validity of the shares to be issued under the new agreement and the resale shares.
Key Facts for Investor Verification
- Verify the current share price and potential dilution impact of a $500 million ATM program.
- Confirm the identity and ownership percentage of the "Selling Stockholders" (affiliates of Atlas Venture and BVF Partners L.P.) registered for resale.
- Review the full text of the TD Cowen Sales Agreement (Exhibit 10.1) for specific price, time, or size limits the Company may impose.
- Monitor future filings to determine if and when the Company elects to sell shares under the new ATM program.